BICO Group AB (publ) has carried out a primary issuance of shares of approximately SEK 2 billion at a subscription price of SEK 480 per share. The subscription price was determined through an accelerated book-building procedure.
Founded in 2016, BICO Group (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, the company enables its customers to improve people's health and lives for the better.
Carnegie Investment Bank AB and J.P. Morgan AG acted as Joint Global Coordinators and Joint Bookrunners. ABG Sundal Collier AB and Bryan, Garnier & Co acted as Joint Bookrunners. Baker McKenzie acted as legal adviser to Joint Global Coordinators, under Swedish and US law, with an international capital markets team consisting of Henric Roth, Joakim Falkner and Per Blom in Stockholm as well as Megan Schellinger in London.